Diabetes mellitus, andtidiabetics and bone;Diabetes mellitus, antidiabetika a kost

Casopis Lekaru Ceskych

Volumn 149, Issue 6, 2010, Pages 282-284

  Svačina, Stepan ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Diabetic osteopathy; Glucagon like peptid 1; Incretin analogues; Thiazolidindiones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

BONE; DIABETES MELLITUS; DRUG EFFECT; FEMALE; HUMAN; METABOLIC BONE DISEASE; REVIEW;

BONE AND BONES; BONE DISEASES, METABOLIC; DIABETES COMPLICATIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; THIAZOLIDINEDIONES;

EID: 77954275247     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Fisman EZ, Tenenbaum A. (eds.) Cardivascular diabetology. Advances in kardiology vo. 45. Basel: Karger 2008.
2. Pickup JC, Williams G. (eds.) Textbook of diabetes. Blackwell 2004; kap. 61.10.
3. Adaml S. Bone health in diabetes: considerations for clinical management. Cuir Med Res Opin 2009; 25(5): 1057-1072.
4. Strotmeyer ES, et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 2005; 165(14): 1612-1617.
5. Strotmeyer ES, et al. Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: The Health, Aging, and Body Composition Study. J Bone Miner Res 2004; 19(7): 1084-1091.
6. Fantuzzi G, Mazzone Th. (eds.) Adipose tissue in health and disease. Totowa: Humana Press 2007.
7. Palička V. Leky ovlivnujlcf kostnf metabolismus u diabetikii. Vnitr Lek 2009; 55(4): 368-370.
8. Gao Y, LI Y, Xue J, Jia Y, Hu J. Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats. Eur J Pharmacol 2010; 19. E-pub.
9. Kahn SE, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008; 31(5): 845-851.
10. Zinman B, et al: Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab 2010; 95(1): 134-142.
11. Douglas IJ, Evans SJ, Pocock S, Smeeth L. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med 2009; 6(9): e1000154.
12. Meier C, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168(8): 820-825.
13. Jones SG, Momln SR, Good MW, SheaTK, Patric K. Distal upper and lower limb fractures associated with thiazolidinedione use. Am J Manag Care 2009; 15(8): 491-496.
14. Haluzik M, Svana S. Inkretinová léčba diabetu. Praha: Mladá fronta2010.
15. Bjerre Knudsen L, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151(4): 1473-1486.
16. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide - the FDA's review of a new antidiabetic therapy. N Engl J Med 2010; 362(9): 774-777.
17. Yamada C, et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 2008; 149(2): 574-579.
18. Borm AK. The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus. Horm Metab Res 1999; 31(8): 472-475.